Pseudomonas aeruginosa elastase is a zinc metalloproteinase which is released during P. aeruginosa infections. Pseudomonas keratitis, which occurs following contact lens-induced corneal trauma, can lead to rapid, liquefactive necrosis of the cornea. This destruction has been attributed to the release of both hostderived enzymes and the bacterial products P. aeruginosa elastase, alkaline protease, exotoxin A, and lipopolysaccharide endotoxin. A synthetic metalloproteinase inhibitor, HSCH2 (DL)CH[CH2CH(CH3)2]COPhe-Ala-NH2, which we previously showed to be a potent inhibitor of corneal coliagenase and alkali-induced corneal ulceration, was tested as a potential inhibitor of P. aeruginosa elastase. Inhibition constants (K,s) for the resolved diastereomers were determined with the chromogenic substrate furylacryloyl-glycyl-L-leucyl-Lalanine. One isomer had a K1 of 0.3 ,M, while the other had a Ki of 0.4 ,uM. The more potent diastereomer was evaluated in vivo in experimentally induced Pseudomonas keratitis in rabbits. Following inoculation of one cornea of each rabbit, topical treatment with a 1 mM solution of the inhibitor significantly delayed the onset of corneal melting and perforation, as compared with the results for the control and gentamicin-treated groups. This protective effect suggests that the inhibitor may have a therapeutic application by delaying the progression of corneal destruction in Pseudomonas keratitis.
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Pseudomonas aeruginosa is one of the most commonly encountered organisms found in infectious keratitis (26, 28) . Pseudomonas keratitis causes rapid, liquefactive destruction of the human cornea and is being seen with increasing frequency following corneal trauma from extended-wear contact lenses (7, 12) . Destruction of the cornea in Pseudomonas keratitis results from the release of degradative enzymes from both the organism (3, 16, 18, 24) and hostderived sources (17) . The metalloproteinase P. aeruginosa elastase is one of the main enzymes released by P. aeruginosa and is thought to be a major contributor to the pathogenesis of the organism (16, 24) .
It has been demonstrated that immunization of rabbits and mice with elastase provides protection from Pseudomonas keratitis (25) . Recent studies have suggested that inhibition of P. aeruginosa elastase may lead to more effective therapeutic approaches to this disease (19, 21, 22) . Compounds which inhibit metalloproteinases such as P. aeruginosa elastase have been shown to alter the clinical course of Pseudomonas keratitis. The compound 2-mercaptoacetyl-LPhe-L-Leu, an inhibitor of P. aeruginosa elastase (17) , reduced the amount of corneal melting in experimental Pseudomonas keratitis in rabbits when combined with gentamicin (31) . Recently, tetracycline was shown to reduce the incidence of alkali-induced corneal ulceration (30) and Pseudomonas keratitis-induced corneal perforation in rabbits (27) . This effect was thought to be secondary to the anticollagenase effect of tetracycline.
The metalloproteinase inhibitor HSCH2 (DL)CH[CH2CH (CH3)2]CO-Phe-Ala-NH2 is a potent inhibitor of mammalian collagenases, such as pig synovial collagenase (8) and purified collagenase from alkali-burned rabbit corneas (6) . It also inhibits alkali-induced corneal ulceration and perforation in rabbits (4) . In the present study, we found that the peptide is * Corresponding author. a potent inhibitor of P. aeruginosa elastase in vitro. Because the peptide inhibited both corneal collagenase and elastase, we postulated that the inhibitor would be more effective against Pseudomonas keratitis than are compounds which inhibit only elastase (31) . Our findings indicate that the inhibitor slowed the progression of Pseudomonas keratitis and was more effective than was either vehicle or topical gentamicin in this model.
MATERIALS AND METHODS
Bacterial strain and growth conditions. A virulent strain of P. aeruginosa, PA-28 (donated by P. V. Liu, Department of Microbiology and Immunology, University of Louisville School of Medicine), was used throughout this study. Stock cultures were kept frozen in Trypticase soy broth with 20% glycerol at -20°C. For enzyme production, bacteria were incubated with shaking at 37°C for 48 h in Mueller-Hinton broth (Difco Laboratories).
Elastase purification. P. aeruginosa elastase was purified from the bacterial filtrate by ammonium sulfate precipitation (60% saturation) and molecular sieve chromatography with a Bio-Gel AO.5m column as previously described (18) . An azocasein assay was used to separate elastase from alkaline protease (17) . Solutions of the purified enzyme (0.4 to 1.2 mg/ml) in 0.01 M Tris hydrochloride (pH 7.45) were stored in aliquots at -20°C.
Inhibitors. The thiol inhibitors were synthesized and characterized as described previously (8, 11) . The diastereomers were resolved by C18 reversed-phase high-pressure liquid chromatography. The inhibitors were dissolved in 95% ethanol containing 1 mM acetic acid immediately prior to use, and the thiol titers were determined by the Ellman procedure (9) .
Enzyme assays. The chromogenic substrate furylacryloylglycyl-L-leucyl-L-alanine (FA-Gly-Leu-Ala) was prepared as previously described (2 (17) .
Inhibitor and antibiotic preparation for in vivo studies. The inhibitor used for topical and subconjunctival treatment was prepared in the same manner as that described previously (4) , with the exception that the inhibitor was dissolved in dimethyl sulfoxide instead of ethyl alcohol and acetic acid. The final inhibitor concentration was 1 mM. Vehicle was also prepared as previously described, with the exception that dimethyl sulfoxide was used instead of ethyl alcohol and acetic acid (4 Bacterial preparation for in vivo studies. P. aeruginosa PA-28 is susceptible to gentamicin in vitro (MIC, 2 j±g/ml). Stock cultures of the organism were kept in Trypticase soy broth with 20% glycerol at -20°C. For experiments, a suspension of organisms from the stock was grown overnight on Mueller-Hinton agar. Direct inoculations were then made from the overnight agar growth into Mueller-Hinton broth (20 ml) in 250-ml shaker flasks. Extra Ca2" (50 ,ug/ml) and Mg2+ (20 ,g/ml) were added to the broth to increase protease production (32) . The suspension was incubated with shaking at 37°C for 16 to 18 h. At the end of the incubation period, the suspension was diluted to an A64o of 0.2 with Mueller-Hinton broth. This value corresponded to a final concentration of 6 .0 x 108 cells per ml.
Corneal inoculations and treatment regimens. Forty-eight New Zealand White rabbits weighing between 2 and 2.5 kg were used. The methods used in this study were in accord with the Association for Research in Vision and Ophthalmology Resolution for the Use of Animals in Research. The animals were anesthetized by intramuscular injection of ketamine hydrochloride (37.5 mg/kg) and xylazine hydrochloride (5 mg/kg) and by topical application of tetracaine. Following anesthetization, one eye of each animal was subjected to proptosis, and a central area of corneal epithelium approximately 4 mm in diameter was removed by scraping with a scalpel blade. Twenty microliters of the P. aeruginosa cell suspension (1.2 x 107 cells) was injected intrastromally into the center of the cornea with the use of a 30-gauge needle and a 100-,u Hamilton syringe. All injections were performed with the aid of a stereoscopic microscope. Animals were given buprenorphine hydrochloride (0.05 mg/kg) intramuscularly as needed for pain control.
In three independent experiments, the rabbits were divided randomly into either a treatment group or a control group (six eyes per group in experiment A and nine eyes per group in experiments B and C). Experiment A included a group treated with inhibitor both topically and subconjunctivally according to the treatment schedule in Table 1 . In experiment A, topical treatment was begun 2 h following bacterial inoculation. The control group received vehicle ?rogression of Pseudomonas keratitis in inhibitor-treated (n postinoculation). Thus, the peptide significantly slowed the vehicle-treated (n = 9) corneas. The x axis corresponds to onset of corneal melting and perforation. No corneal melting postinoculation, and the y axis corresponds to the average was noted in the inhibitor-treated eyes until 12 h postinocuscore (Table 2) . Scores for corneas which were perforated lation, at which time five of the nine control eyes already had :he end of the experiment continued to be included in perforated corneas. vehicle only (balanced salt solution) according to the same treatment schedule as that used in experiment B. The results are shown in Fig. 3 . Treatment with fortified gentamicin had no protective effect against corneal destruction. There was no significant difference between the mean clinical scores for the gentamicin-treated and vehicle-treated eyes at any time following inoculation of the corneas. At 12 h postinoculation, six of nine gentamicin-treated corneas were perforated, as were six of nine vehicle-treated corneas. DISCUSSION P. aeruginosa has become a commonly isolated pathogen in bacterial keratitis (26, 28) . The rise in its occurrence has been attributed to the increased use of extended-wear contact lenses (7, 12) . Following adherence of the organism to a damaged corneal epithelium (14, 29) , the release of exogenous enzymes, including proteases (16), elastases (16, 24) , and exotoxins (1, 13, 15) , is necessary for stromal penetration of the organism to occur. Evidence suggests that these enzymes contribute to corneal destruction (3, 16, 18, 24) and that their inhibition may lead to a reduction in the amount of corneal destruction which occurs (17, 22, 23) .
The extracellular protease P. aeruginosa elastase is thought to contribute to the rapid liquefactive dissolution of the cornea during Pseudomonas keratitis (16, 24) . Spierer and Kessler (31) demonstrated that the compound 2-mercaptoacetyl-L-Phe-L-Leu, an inhibitor of P. aeruginosa elastase (17) , had a protective effect against Pseudomonas keratitis when combined with gentamicin. The effect was significant at 28 h but not at 48 h postinoculation (31) . A recent study (27) also showed that systemic tetracycline treatment reduced corneal perforation due to Pseudomonas keratitis in rabbits from 80 to 45% over a period of 10 days. This effect was independent of any antimicrobial effect and was hypothesized to be secondary to the anticollagenase activity of tetracycline (27) . The recent finding by our laboratory that tetracycline compounds inhibit P. aeruginosa elastase suggests that the reduction in corneal pathology may be due to this action instead of or in addition to the anticollagenase activity of tetracycline (5) .
In addition to the enzymes released by the organism, host-derived sources of degradative enzymes appear to play a role in the destructive nature of Pseudomonas keratitis. A previous study demonstrated that when heat-killed P. aeruginosa cells were injected intrastromally into the cornea, corneal melting and ulceration progressed in a manner similar to that seen with live P. aeruginosa (19) . Analysis of the corneal tissue revealed the presence of collagenolytic activity in the ulcerating corneas, and histologic examination revealed an influx of polymorphonuclear leukocytes into the corneal stroma. Thus, it was hypothesized that host-derived collagenase and other proteases may play a significant role in the rapid corneal melting seen in Pseudomonas keratitis.
We have shown in the present study that the synthetic metalloproteinase inhibitor HSCH2 (DL)CH[CH2CH(CH3)2] CO-Phe-Ala-NH2 inhibits P. aeruginosa elastase. We showed previously that it is a powerful inhibitor of corneal and synovial collagenases (6, 8) and also inhibits alkaliinduced corneal ulceration and perforation in rabbits (4) . Because our compound inhibited both P. aeruginosa elastase and corneal collagenase, we felt that it may provide more corneal protection against Pseudomonas keratitis than does the compound evaluated by Spierer and Kessler (31) . The large inoculum used in the present study (1.2 x 107 organisms) was chosen to evaluate the response of the inhibitor to rapidly destructive keratitis, similar to the model used by Spierer and Kessler (31) . Treatments were begun at time zero in experiments B and C because of the large inoculum and the rapid progression of corneal melting noted in experiment A. Our results indicate that the inhibitor delayed the onset of corneal melting and perforation in this model of Pseudomonas keratitis. We also found that increasing the frequency of topical therapy resulted in a longer delay in the onset of corneal melting and perforation. Finally, we showed that therapy with topical fortified gentamicin had no effect upon corneal destruction in this model. This finding was of interest because the organism was highly susceptible to gentamicin in vitro (MIC, 2 p.g/ml). The most likely explanation for this is that the gentamicin could not kill such a large inoculum of organisms (1.2 x 107). Another explanation may be that the broth had such a high concentration of enzymes when injected into the cornea that the inhibition of bacterial growth could not prevent the rapid corneal destruction which occurred. The inhibitor most likely had no effect upon bacterial growth within the cornea, as Kessler and Safrin have shown that thiol-based protease inhibitors do not affect the growth of P. aeruginosa in cultures (20) .
The inhibitory effect of the peptide did not last through 24 h. One explanation may be that other enzymes which were not inhibited by the peptide were released by the organism. Polymorphonuclear leukocytes, which readily infiltrate the cornea in bacterial keratitis, could also have released degradative enzymes, such as polymorphonuclear leukocyte elastase, which were not inhibited by the peptide. The organism may have inactivated the inhibitor, as is the case with other thiol-based peptides (21) .
It is well recognized that even with optimum antibiotic therapy begun as soon as a corneal ulcer is detected, the cornea often progresses rapidly to melting, ulceration and, frequently, perforation (26, 28) . In the case of Pseudomonas keratitis, progression to perforation can occur as early as 2 to 5 days following initial presentation. In these cases, it seems likely that additional therapeutic measures which are aimed at inhibiting the enzymes produced by the organism and by the host would have a beneficial effect when combined with an appropriate antibiotic regimen. We believe that the present study demonstrates that our synthetic metalloproteinase inhibitor may aid in the prevention of corneal melting and perforation in Pseudomonas keratitis.
